Clinical Trials Sponsored by Geistlich Pharma AG

Total 556 results

Grupo Espanol de Tumores Neuroendocrinos
Roche Pharma AG; Ipsen

Active, not recruiting

Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study (CABATEN)

Adenocarcinoma | Neuroendocrine Tumor | Pheochromocytoma | Paraganglioma | Anaplastic Thyroid Cancer

Spain
University College, London
Roche Pharma AG; Cancer Research UK

Active, not recruiting

Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

Lymphoma

New Zealand, United Kingdom, Australia
Fundacion SEIMC-GESIDA
Roche Pharma AG; Dynamic Science S.L.

Completed

Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia

COVID-19

Spain
University of British Columbia
Roche Pharma AG; Health Canada

Enrolling by invitation

COVID-19 Rapid Testing for Self-Administration Among an Asymptomatic Sample

Covid19 | Asymptomatic Shedding Viral

Canada
Instituto Valenciano de Infertilidad, IVI VALENCIA
Roche Pharma AG

Completed

Follicular Steroid Genesis in Controlled Ovarian Stimulation (ESTEFOL)

Infertility | Controlled Ovarian Hyperstimulation

Spain
Universidad de Valparaiso
GlaxoSmithKline; Roche Pharma AG; Aclin Laboratory

Completed

Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV . (CORE-HIV)

Hepatitis B | HIV

Chile
Ohio State University Comprehensive Cancer Center
Roche Pharma AG

Terminated

Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary

Adenocarcinoma | Tumors | Unknown Primary Tumors

United States
SCRI Development Innovations, LLC
Roche Pharma AG; Sanofi-Synthelabo

Completed

Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site

Neoplasms, Unknown Primary

United States
Karolinska University Hospital
Roche Pharma AG; Addoz; Tele2Sverige AB

Completed

Compliance/Adherence After Kidney Transplant, With or With Out Med-O-Wheel™. (C/A)

Communication | Medication Adherence | Medication Nonadherence | Compliance | Transplant; Failure, Kidney

Sweden
University of North Carolina, Chapel Hill
Roche Pharma AG

Completed

Overcoming Psychiatric Barriers to the Treatment of Hepatitis C

Hepatitis C | Substance Use Disorders | Mental Disorder

United States
Seoul National University Hospital
Roche Pharma AG; SciClone Pharmaceuticals

Completed

Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of
Association Européenne de Recherche en Oncologie
Roche Pharma AG

Unknown

Xeloda Vs Monitoring in Advanced Colorectal Cancer Responsive to Chemotherapy

Colorectal Cancer

France
Latin American Cooperative Oncology Group
Roche Pharma AG; Oncoclínicas

Not yet recruiting

Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade (CHERRY-PICK)

Breast Cancer | HER2-positive Breast Cancer

Brazil
Medical University of Vienna
Roche Pharma AG; Allcyte GmbH

Recruiting

Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies (EXALT-2)

Refractory Acute Myeloid Leukemia | Advanced Lymphoma | Refractory Lymphoma | Refractory Leukemia | Refractory T-Cell Lymphoma

Austria
Ulrik Lassen
GlaxoSmithKline; Pfizer; Roche Pharma AG

Recruiting

ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling (ProTarget)

Neoplasms | Cancer | Tumors | Neoplasia

Denmark
University of Birmingham
Roche Pharma AG; Cancer Research UK

Recruiting

NOSTRA-Feasibility Study: A Study Looking at Ultrasound Guided Biopsies for Breast Cancer (NOSTRA)

Breast Cancer

United Kingdom
Mario Negri Institute for Pharmacological Research
Roche Pharma AG

Active, not recruiting

Obinutuzumab in Primary MN (ORION)

Membranous Nephropathy

Italy
Instituto Nacional de Cancerologia de Mexico
Roche Pharma AG

Active, not recruiting

Tocilizumab Treatment in Patients With COVID-19

Sars-CoV2

Mexico
SOLTI Breast Cancer Research Group
Roche Pharma AG; Amgen

Active, not recruiting

Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer (PROMETEO)

Breast Cancer

Spain
Ludwig Institute for Cancer Research
Pfizer; Heidelberg Pharma AG

Terminated

Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma

Renal Cell Carcinoma (RCC)

Australia
Instituto Valenciano de Infertilidade de Lisboa
Roche Pharma AG

Completed

Determination of Circulating Placental Biomarkers Levels to Predict the Pregnancy Outcome of First Trimester After IVF.

Infertility, Female | First Trimester Spontaneous Abortion

Portugal
Karoline Krause
Roche Pharma AG

Completed

Tocilizumab in Patients With Schnitzler's Syndrome (TOCISCH)

Schnitzler's Syndrome

Germany
Western Health and Social Care Trust
Roche Pharma AG

Unknown

CINtec PLUS Triage in HPV Primary Screening

Cervical Cancer

United Kingdom
Patrick Veit-Haibach
Roche Pharma AG

Terminated

Visualization of Anti-angiogenic Effects With Perfusion Computed Tomography (CTP) (AVA-CTP)

Metastatic Colorectal Cancer

Switzerland
University College, London
Roche Pharma AG; Cancer Research UK

Completed

Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer (TOPICAL)

Lung Cancer

United Kingdom
Groupe Francophone des Myelodysplasies
Roche Pharma AG; Celgene Corporation

Completed

Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)

Myelodysplastic Syndromes

France
University of Cincinnati
Roche Pharma AG; University of Tennessee

Completed

A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients

Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients

United States, Canada
South Eastern European Research Oncology Group
Roche Pharma AG

Unknown

Bevacizumab and Capecitabine in Treatment of Elderly Patients With Metastatic Breast Cancer

Breast Cancer | Metastasis

Croatia
Hospital Clinic of Barcelona
Astellas Pharma Inc; Fresenius AG

Terminated

Induction Treatment Followed by Immunosuppression Withdrawal in Liver Transplantation: A Comparative Trial (ATEGE-LIVER)

Liver Diseases

Spain
Deok-Hwan Yang
Roche Pharma AG

Unknown

A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment

Chronic Lymphocytic Leukemia

Korea, Republic of
German CLL Study Group
Mundipharma Pte Ltd.; Roche Pharma AG

Completed

FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany
Lund University Hospital
Mundipharma Pte Ltd.; Roche Pharma AG; Celgene

Completed

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. (LENA-BERIT)

Mantle Cell Lymphoma

Finland, Denmark, Norway, Sweden
University Hospital, Tours
Roche Pharma AG; French Innovative Leukemia Organisation

Completed

Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia (LLC2007SA)

Leukemia

France
German Breast Group
GlaxoSmithKline; Roche Pharma AG; Teva Pharmaceuticals USA

Completed

Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer (GeparSixto)

Inflammatory Breast Cancer | HER-2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III | Inflammatory Breast Cancer Stage IV

Germany
TME Pharma AG
German Federal Ministry of Education and Research

Completed

NOX-A12 First-in-human (FIH) Study

Autologous Stem Cell Transplantation

Germany
University of Texas Southwestern Medical Center
Roche Pharma AG; Biogen

Completed

Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis

Multiple Sclerosis

United States
Jean-Luc Van Laethem
Roche Pharma AG

Unknown

Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer (NEOPACHI-001)

Pancreatic Adenocarcinoma Resectable

Belgium
The HIV Netherlands Australia Thailand Research...
Roche Pharma AG

Completed

Study of Genetic Polymorphisms in Thai HIV-1 Infected Patients on SQV/r

HIV Infections

Thailand
Assistance Publique - Hôpitaux de Paris
Roche Pharma AG; Roche Chugai

Recruiting

Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement (TOGIAC)

Giant Cell Arteritis | Neurovascular Disorder

France
The Netherlands Cancer Institute
Roche Pharma AG; Borstkanker Onderzoek Groep

Active, not recruiting

Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 (TRAIN-2)

Breast Cancer | HER2 Positive

Netherlands
Sucampo Pharma Americas, LLC
Sucampo AG; Sucampo Pharmaceuticals, Inc.

Completed

Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo

Chronic Idiopathic Constipation

United States
Rennes University Hospital
Roche Pharma AG; National Research Agency, France

Completed

BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology (BMS_PD-L1)

Hodgkin Lymphoma | Non-small Cell Lung Cancer | Diffuse Large B-cell Lymphoma | Metastatic Breastcancer

France
University Hospital Inselspital, Berne
Roche Pharma AG; University of Bern

Completed

Tocilizumab for Patients With Giant Cell Arteritis

Giant Cell Arteritis

Switzerland
Jinming Yu
Roche Pharma AG

Unknown

Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21 (RECEL)

Non-small Cell Lung Cancer

China
National Bone Health Alliance
Roche Pharma AG; National Osteoporosis Foundation

Unknown

Changes in Biochemical Markers of Bone Turnover (Serum CTX and PlNP) After Initiation of a "Drug Holiday" From Bisphosphonates

Osteoporosis

United States
Aktion Bronchialkarzinom e.V.
Eli Lilly and Company; Roche Pharma AG

Withdrawn

TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV (SELECT-A)

Carcinoma, Non-Small-Cell Lung
University of Minnesota
Juvenile Diabetes Research Foundation; Roche Pharma AG

Completed

Delayed Mycophenolate Mofetil in Single-Donor Islet Allotransplantation in Type 1 Diabetes

Hypoglycemia | Type 1 Diabetes

United States
Salvador Gil-Vernet
Roche Pharma AG

Completed

Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients

Cytomegalovirus Infection

Spain
Canadian Cancer Trials Group
AbbVie; Roche Pharma AG; Incyte Corporation

Recruiting

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Lymphoma, B-Cell

Canada
The Netherlands Cancer Institute
Roche Pharma AG; Borstkanker Onderzoek Groep

Active, not recruiting

Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer (Triple-B)

Breast Cancer

Netherlands

Clinical Trials Sponsored by Geistlich Pharma AG

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations